Why the study?
The clinical utility of doxorubicin is limited by cardiomyopathy, necessitating the identification of effective treatments and cardioprotective strategies against doxorubicin-induced cardiomyopathy.
Do current and emerging pharmacological and natural treatments mitigate doxorubicin-induced cardiomyopathy in human and animal models?
Comparison
Current and emerging treatments for doxorubicin-induced cardiomyopathy
Design
Review
Authors
Loading...
I need the paper’s actual verdict and evidence level before writing the implication. Searching Cureus for the doxorubicin cardiomyopathy review.Opening the Cureus review to extract the authors’ verdict and conclusions.The article pages didn’t return the full text. Trying the PDF and Europe PMC.Opening the PDF for the review’s conclusions and key finding.Pulling the conclusions section to lock the
Do current and emerging pharmacological and natural treatments mitigate doxorubicin-induced cardiomyopathy in human and animal models?
A variety of pharmacological and natural agents show promise in mitigating doxorubicin-induced cardiomyopathy in preclinical models, highlighting the need for further clinical trials in patients with preexisting cancer.
Kabir et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: